PARG is a next-generation DDR target with significant potential in PARP inhibitor-resistant cancers Preclinical data show high potency across multiple solid tumor cell lines and in vivo models, including those resistant to PARP inhibitors Presentation also includes molecular structure and discovery data Initial data from an open-label Phase 1 study of FORX-428 in patients with advanced solid tumors expected mid-2026 March 26, 2026 – FoRx Therapeutics, a clinical-stage biotechnology company de

March 26, 2026 – SignaBlok, Inc., a preclinical stage biotechnology company pioneering novel, first-in-class peptide therapies for multiple inflammation-associated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company’s TREM-1 peptide inhibitor for the treatment of retinopathy of prematurity (ROP). “Orphan Drug Designation for ROP represents a significant milestone in the development of our TREM-1 therapy for the treatment

March 24, 2026 -- RyboDyn, Inc., a biotechnology company decoding the dark proteome using an AI-powered novel sequencing and discovery platform, today announced the initial close of a $10M Seed financing from a syndicate of new and existing investors. The financing will accelerate the company's transition from foundational discovery into scaled platform execution and progress early-stage programs into IND-enabling studies. RyboDyn founders Imad Ajjawi, PhD (left), and Corey Dambacher, PhD (righ

March 24, 2026 -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a securities purchase agreement with RA Capital Management for a private placement that is expected to result in gross proceeds of approximately $30 million before deducting placement agent fees and offering expenses, and an additional approximately $44 million of gross proceeds if the accompanying warrants are exerci

March 24, 2026 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that the Investigational New Drug (IND) application for SKB103, its self-developed novel bispecific antibody-drug conjugate with combined Tumor-Associated Antigen-targeting and Immuno-Oncology mechanisms (TAA-PD-L1 bsADC), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of advan

March 24, 2026 -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic malignancies and autoimmune diseases, today announced that its Clinical Trial Notification (CTN) for its independently developed, fully human BCMA-targeted CAR-T cell therapy, Equecabtagene Autoleucel (Eque-cel), has been cleared by Japan's Pharmaceuticals and Medical Devic

Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung cancer March 24, 2026 -- Prestige Biopharma today announced positive topline results from its Phase 3 SAMSON-II study evaluating HD204, a proposed biosimilar to Avastin® (bevacizumab) in adult patients with advanced non-squamous non-small cell lung cancer (NSCLC). SAMSON-II is a randomized, double blind, parallel group, multicenter Phase 3 stud

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo BP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense itch alongside painful blisters and other lesions BP is the seventh approved indication for Dupixent in Japan March 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sa

New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing Expertise Fuchs Endothelial Corneal Dystrophy (FECD) Afflicts More Than 7.3% of the Population with a Predicted 10-Year CAGR of 7.7% Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the expansion of its cell transplant pipeline wi

PK studies of topical HT-001 reveal limited systemic absorption and ~99% reduced systemic levels as compared to FDA approved oral formulations. Safety and tolerability findings included: No serious adverse events (0%) No dose-limiting toxicities observed. No treatment discontinuations due to adverse events Day 42 Data Show Higher AUC, Cavg, and Cmax vs Day 1, with ~2.1x Accumulation Supporting Sustained Drug Exposure, Consistent Tolerability, and Clinically Meaningful Response March 24, 2026